Cargando…
Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
BACKGROUND: The FLAURA study was a multicenter, double-blind, Phase 3 study in which patients with previously untreated epidermal growth factor receptor mutation-positive advanced non-small-cell lung carcinoma were randomized 1:1 to oral osimertinib 80 mg once daily or standard-of-care (gefitinib 25...
Autores principales: | Ohe, Yuichiro, Imamura, Fumio, Nogami, Naoyuki, Okamoto, Isamu, Kurata, Takayasu, Kato, Terufumi, Sugawara, Shunichi, Ramalingam, Suresh S, Uchida, Hirohiko, Hodge, Rachel, Vowler, Sarah L, Walding, Andrew, Nakagawa, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322567/ https://www.ncbi.nlm.nih.gov/pubmed/30508196 http://dx.doi.org/10.1093/jjco/hyy179 |
Ejemplares similares
-
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
por: Cheng, Ying, et al.
Publicado: (2021) -
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
por: Yoh, Kiyotaka, et al.
Publicado: (2021) -
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression
por: Abdayem, Pamela, et al.
Publicado: (2020) -
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
por: Hirashima, Tomonori, et al.
Publicado: (2019) -
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI
por: Mann, Helen, et al.
Publicado: (2017)